A year after its seed financing, Peptilogics Inc. closed a $5.5 million series A to advance its engineered cationic antibiotic peptide, or ECAP, platform to ply multidrug-resistant (MDR) bacterial infections. The ECAP mechanism enables direct targeting and disruption of bacterial membranes without lysing, causing rapid death of both dormant and growing bacterial cells.